Anacor's AN2728 and GSK '052 new data to be presented at upcoming meetings

Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that it will present data on two of its compounds at the following conferences:

“Safety and efficacy of AN2728 ointment in a phase 2b dose-ranging bilateral study of mild-to-moderate plaque psoriasis”

• 2011 Society for Investigative Dermatology (SID) Annual Meeting
  • Lee Zane, M.D., Anacor's Chief Medical Officer, will present "Safety and efficacy of AN2728 ointment in a phase 2b dose-ranging bilateral study of mild-to-moderate plaque psoriasis" in a poster session on Thursday May 5, 2011 at 10 a.m. MT / 9 a.m. PT.
• 21^st European Congress of Clinical Microbiology and Infectious Diseases
• Liang Liu, Senior Director of Pharmacokinetics and Drug Metabolism, will present "Interspecies scaling for prediction of human intravenous pharmacokinetics of GSK2251052 (GSK '052), a novel boron-based antimicrobial against Gram-negative bacteria" in poster topic 17 on Saturday May 7, 2011 at 3:30 p.m. CET / 6:30 a.m. PT.
• Dr. Zane will present "Safety, tolerability, and pharmacokinetics of a novel Gram-negative antimicrobial, GSK2251052 (GSK '052), in healthy subjects" in poster topic 65 on Monday May 9, 2011 at 12:30 p.m. CET / 3:30 a.m. PT.